May 2026 Prescription Drug Affordability Board Meeting

Meeting Details

The Maryland Prescription Drug Affordability Board invites you to attend the May Board Meeting, scheduled for Monday, May 18, 2026 at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed, registration is not required. You may also attend in person at the following address:

Miller Senate Building, William Amoss Room, 4th Floor

11 Bladen Street

Annapolis, MD 21401

The meeting will be livestreamed at this link HE​​​​RE.

• Date and time: May 18th, 2026 2:00 pm to 4:00 pm
• Address:

  11 Bladen Street
  Annapolis, MD 21401
  United States

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, May 13, 2026, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]​​​. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, May 13, 2026. Please utilize the subject line “September 2026 Board Comments.”

Agenda and Meeting Materials

• Agen​​da (revised 5/11/26)​​ - PDF - 123.97 KB
• Meeting Recor​ding
• Staff Recommendations to Update the Cost Review Study Process and Policy Review Process Regulations- Presentation - PDF - 157.34 KB
• Draft-Amendments to COMAR 14.01.04- Cost Review Study Process​  - PDF - 296.97 KB
• Ozempic- Cost Review Study Report- Presentation - PDF - 164.97 KB
• Ozempic Cost Review Study Report (5/11/2026)​ - PDF - 14.44 MB
  • ​Appendix A Excel Exhibits:
    • Exhibit 3​ ​       Ozempic Therapeutic Alternative Pricing_REDACTED (Excel Document) - XLSX - 306.33 KB
    • Exhibit 4        Ozempic Therapeutic Alternative​ Medical Claims Data Base (MCDB) Statistics (Excel       Document)​​ - XLSX - 150.18 KB
    • Exhibit 5
      • ​Exhibit 5A      Ozempic Summary of Cost Effectiveness Analyses  - XLSX - 19.9 KB
      • Exhibit 5B      Ozempic Summary of Comp​arative Effectiveness Research   - XLSX - 25.69 KB
• Ozempic- Non-UPL Policies- Presentation - PDF - 255.06 KB
• Non-UPL Policy- Plan Design and PBM Reform Study and Recommendations - PDF - 66.57 KB
• Non-UPL Policy- GLP-1 Study and Recommendations​ - PDF - 72.41 KB
• Non-UPL Policy- Bulk Purchasing/Subscription Model - PDF - 60.49 KB
• Non-UPL Policy- Patient Navigator Program - PDF - 84.82 KB
• Non-UPL Policy- State Participation in CMMI Models - PDF - 69.01 KB
• ​​Ozempic: Calculatio​ns and Analysis Underpinning Potential UPL Values - PDF - 195.36 KB
  • Written Comment Packet- Ozempic: Calculations and Analysis Underpinning Potential UPL Values- Received May 1, 2026 - PDF - 646.06 KB
• ​​Ozempic- Consideration of Upper Payment ​Limit- Presentation​ - PDF - 235.67 KB
  • Draft COMAR 14.01.07.02- Upper Payment Limit for Ozempic (Clean) - PDF - 96.82 KB
  • Draft COMAR 14.01.07.02- Upper Payment Limit for Ozempic (Redlined)​ - PDF - 96.98 KB
  • ​​Written Comment Packet- Draft Proposed Regulations- 14.01.07.02- Received May 1, 2026​ - PDF - 1.11 MB
• Recommended Revision to Board Adopted Proposed- COMAR 14.01.07.01
  • COMAR 14.01.07.01- Clean - PDF - 116.58 KB
  • COMAR 14.01.07.01- Redlined - PDF - 117.09 KB
• Board Meeting Written Co​mment Packet - PDF - 884.74 KB- Comments Received from the following:
  • AARP
  • Community Access National Network
  • EACH/PIC Coalition
  • Let My Doctors Decide Action Network